Voyager Therapeutics, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Voyager Therapeutics, Inc
The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.
The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Third Rock Ventures, LLC